News Sentiment

PMN sentiment intelligence

ProMIS Neurosciences Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.25 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+6.7% over one week, +37.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.7% Price confirming higher
Trend fit Trend inactive 37.7% over four weeks
Fair value -48.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 8
TradingView 7
TradingKey 5
GlobeNewswire 3
simplywall.st 3
GuruFocus 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 15
Analyst action 7
Capital return 1
Guidance 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
Stock Titan Direct company coverage

ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike

ProMIS Neurosciences Inc. CEO Neil K. Warma has been granted 160,000 stock options with an exercise price of $10.77 per share. These options, which expire on May 20, 2036, will vest ratably over four years, contingent on his continued service to the company. The grant is primaril

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 14:09
Source
Stock Titan
Stock Titan Direct company coverage

ProMIS Neurosciences (PMN) director granted options on 16,500 shares

ProMIS Neurosciences (PMN) director Eugene Williams was granted options for 16,500 common shares on May 20, 2026, as part of his compensation. The options include 11,000 shares vesting fully by May 20, 2027, and 5,500 shares with 25% vesting immediately, and the rest ratably over

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 14:09
Source
Stock Titan
Stock Titan Direct company coverage

ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years

ProMIS Neurosciences Inc. (PMN) has awarded its Chief Scientific Officer, Neil Cashman, 50,000 stock options. These options, with an exercise price of $10.77 per share and an expiration date of May 20, 2036, will vest ratably over four years, contingent on his continued service t

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 02:08
Source
Stock Titan
Stock Titan Direct company coverage

ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price

ProMIS Neurosciences Inc. director William W. Wyman was granted two stock option awards for a total of 16,500 common shares. These options have an exercise price of $10.77 per share and an expiration date of May 20, 2036. The vesting schedules differ for each grant, with one vest

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 01:39
Source
Stock Titan